The challenge of systemic immunoglobulin light-chain amyloidosis (Al).

Giovanni Palladini, Raymond L. Comenzo

Research output: Contribution to journalArticle

Abstract

The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.

Original languageEnglish
Pages (from-to)609-642
Number of pages34
JournalSub-Cellular Biochemistry
Volume65
Publication statusPublished - 2012

Fingerprint

Immunoglobulin Light Chains
Transplants
Poisons
Amyloidosis
Amyloid
Stem cells
Viscera
Plasma Cells
Plasmas
Stem Cells
Therapeutics
Clone Cells
Light
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The challenge of systemic immunoglobulin light-chain amyloidosis (Al). / Palladini, Giovanni; Comenzo, Raymond L.

In: Sub-Cellular Biochemistry, Vol. 65, 2012, p. 609-642.

Research output: Contribution to journalArticle

@article{555a893fd1454f429d0fa829f4ceef1d,
title = "The challenge of systemic immunoglobulin light-chain amyloidosis (Al).",
abstract = "The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 {\%} who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.",
author = "Giovanni Palladini and Comenzo, {Raymond L.}",
year = "2012",
language = "English",
volume = "65",
pages = "609--642",
journal = "Sub-Cellular Biochemistry",
issn = "0306-0225",
publisher = "Plenum Publishers",

}

TY - JOUR

T1 - The challenge of systemic immunoglobulin light-chain amyloidosis (Al).

AU - Palladini, Giovanni

AU - Comenzo, Raymond L.

PY - 2012

Y1 - 2012

N2 - The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.

AB - The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.

UR - http://www.scopus.com/inward/record.url?scp=84889658374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889658374&partnerID=8YFLogxK

M3 - Article

C2 - 23225018

AN - SCOPUS:84889658374

VL - 65

SP - 609

EP - 642

JO - Sub-Cellular Biochemistry

JF - Sub-Cellular Biochemistry

SN - 0306-0225

ER -